2Seventy Bio

2Seventy Bio Accounts Payable

Delisted

The Accounts Payable of 2Seventy Bio (TSVT) as of Nov 18, 2026 is 1.06 M USD. In the previous year, Accounts Payable was 6.03 M USD — a change of -82.50% (lower).

Accounts Payable

1.06 MUSD

YoY

-82.50%

Last updated:

Accounts Payable of 2Seventy Bio is 2024 1.06 M USD. Accounts Payable of 2Seventy Bio was 2023 6.03 M USD. It decreases by -82.50% lower compared to the previous year.

The 2Seventy Bio Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
20.39 M USD
Jan 1, 2020
7.15 M USD
Jan 1, 2021
6.02 M USD
Jan 1, 2022
7.21 M USD
Jan 1, 2023
6.03 M USD
Jan 1, 2024
1.06 M USD
The 2Seventy Bio Accounts Payable history
YEARAccounts PayableYoY
1.06 MUSD-82.50%
6.03 MUSD-16.37%
7.21 MUSD+19.65%
6.02 MUSD-15.77%
7.15 MUSD-64.92%
20.39 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

2Seventy Bio Stock analysis

What does 2Seventy Bio do? 2seventy Bio, Inc. generates revenue through its cell and gene therapy programs, including SC-DARIC33 for pediatric relapsed and refractory acute myeloid leukemia and bbT369 for B-cell non-Hodgkin lymphoma. The company collaborates with Bristol Myers Squibb to deliver Abecma for multiple myeloma patients in the U.S., leveraging its T cell engineering and lentiviral vector technologies. Its clinical and preclinical programs, such as bbT4015 targeting MUC16, form the core of its product pipeline. The company focuses on developing targeted cellular therapies for cancer patients, with Bristol Myers Squibb as a key partner in commercializing Abecma. 2seventy Bio, Inc. operates in the biopharmaceutical sector, targeting patients with specific cancer types through its advanced therapies. Its products are developed using proprietary T cell engineering and lentiviral vector delivery systems. The company's revenue streams include clinical trial partnerships and potential future commercial sales of its therapies. Bristol Myers Squibb supports the U.S. distribution of Abecma, a key product in its portfolio. 2Seventy Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2Seventy Bio stock

Accounts Payable of 2Seventy Bio is 1.06 M USD in 2024.

Accounts Payable of 2Seventy Bio changed from 6.03 M USD to 1.06 M USD, representing a -82.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable 2Seventy Bio since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's 2Seventy Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — 2Seventy Bio

All Key Metrics — 2Seventy Bio